Breast cancer (all types)
Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share.
Overview
Breast cancer arises from the milk ducts or lobules and is classified by the receptors on its cells: oestrogen and progesterone receptors, and HER2. Hormone receptor-positive, HER2-negative disease is treated with endocrine therapy and CDK4/6 inhibitors; HER2-positive disease with HER2 antibodies and antibody-drug conjugates; triple-negative disease with chemotherapy, immunotherapy and, for BRCA carriers, PARP inhibitors. Ductal carcinoma in situ is a precursor confined to the duct, and about one percent of cases occur in men. Screening mammography from around age 50, breast-conserving surgery with radiotherapy, sentinel node biopsy and genomic tests that spare chemotherapy are common to all types. Most patients present early and are cured; metastatic disease is treatable for years but rarely curable.
State of the art
- Antibody-drug conjugates such as trastuzumab deruxtecan have redrawn the HER2 boundary and moved into HER2-low disease.
- Genomic tests spare most node-negative hormone receptor-positive patients chemotherapy.
- Omission of radiotherapy in older low-risk women and one-week hypofractionation are reducing treatment burden.
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Five-year survival above 90 percent in early disease across high-income countries, driven by screening, endocrine therapy and HER2-targeted drugs.
Anatomy and lymph node drainage
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
- Ducts (most cancers start here)HR-positive / HER2-negative breast cancer · HER2-positive breast cancer · Ductal carcinoma in situ (DCIS)
- Lobules (lobular carcinoma)Invasive lobular carcinoma
- Upper outer quadrant (commonest site)
- Nipple-areola
- axillary level I
- axillary level II-III
- internal mammary
- supraclavicular
Same organ: Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS)
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- The commonest cancer worldwide, with about 2.3 million new cases and 670,000 deaths a year; in high-income countries about nine in ten women diagnosed are alive five years later.
- Mammography & tomosynthesisStandard of care
- AI in radiologyEstablished
- cfDNA fragmentomicsEstablished
- Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)Standard of care
- DNA methylation profilingEstablished
- HCC surveillance in cirrhosis (ultrasound + AFP)Standard of care
- A 28-day national pathway for people with a positive multi-cancer blood test
- A breath test to rule out cancer in people with vague symptoms
- A cancer blood test for older people arriving at A&E with unexplained symptoms
- A legislated, publicly reported 28-day standard from urgent referral to diagnosis
- A live national dashboard of stage at diagnosis as the scorecard for early detection
- A single 'cancer check at 60' appointment bundling all screening tests
Background: Alpha-fetoprotein (AFP), Barrett's oesophagus, CA 19-9, Early detection, Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
Mammography every one to three years from around age 40 to 50 depending on country; MRI for high-risk women.
Breast-conserving surgery with radiotherapy or mastectomy, sentinel node biopsy, then treatment by receptor type on the subtype pages.
Surgery with or without radiotherapy and endocrine therapy; active surveillance under study.
Subtypes & biomarkers
top- Oestrogen and progesterone receptors
- HER2 (including HER2-low)
- Ki-67 and grade
- Genomic recurrence scores (Oncotype DX, MammaPrint)
- BRCA1/2 and other germline variants
- PD-L1 (triple-negative)
- ESR1 and PIK3CA mutations (advanced hormone receptor-positive)
How often this target appears
- 1894Halsted radical mastectomy
The standard operation for seventy years.
- 1977Tamoxifen approved
The first targeted hormonal therapy for breast cancer.
- 1985NSABP B-06: lumpectomy plus radiotherapy equals mastectomy
- 1998Trastuzumab approved
The first HER2-targeted antibody.
- 2000Molecular subtypes described
Perou and Sorlie's expression profiling defines luminal, HER2-enriched and basal-like breast cancers.
- 2015CDK4/6 inhibitors approved
- 2022Trastuzumab deruxtecan in HER2-low disease
What is in development for Breast cancer (all types), drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Open problems and what is being done
Metastatic disease remains incurable for almost everyone.
and how the field plans to fix it →What is being done about thisAdvanced and metastatic diseaseAvailable now- Trastuzumab deruxtecanApproved
- Bone-modifying agents (bisphosphonates, denosumab)Standard of care
- DordaviproneApproved
- HIPEC / PIPAC (intraperitoneal chemotherapy)Established
- Laser interstitial thermal therapy (LITT)Established
- Liquid biopsy (ctDNA)Standard of care
In trials- ACTIONRecruiting
- CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)Phase 1
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- DESTINY-Breast12Positive
- DYNAMICPositive
- EF-14Positive
Ideas and roadmaps- A billion-dollar prize for the first durable cure of a lethal metastatic cancer
- A blood test for the pre-metastatic niche
- A global rapid tissue donation network for metastatic disease
- A national rapid research autopsy network for end-stage cancer
- A regulatory endpoint for drugs that block spread, not tumours
- A ring-fenced metastasis programme with metastasis-specific endpoints
Background: Blood-brain barrier (BBB), Circulating tumour DNA (ctDNA), EGFRvIII, Epithelial-mesenchymal transition & drug efflux, H3 K27M (diffuse midline glioma). Also on OnCo: Atlas of advanced disease · Invasion and metastasis.
Triple-negative and inflammatory breast cancer still have the worst outlook.
Overdiagnosis from screening and overtreatment of low-risk DCIS.
and how the field plans to fix it →What is being done about thisFinding cancer earlierAvailable now- Mammography & tomosynthesisStandard of care
- AI in radiologyEstablished
- cfDNA fragmentomicsEstablished
- Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)Standard of care
- DNA methylation profilingEstablished
- HCC surveillance in cirrhosis (ultrasound + AFP)Standard of care
In trialsIdeas and roadmaps- A 28-day national pathway for people with a positive multi-cancer blood test
- A breath test to rule out cancer in people with vague symptoms
- A cancer blood test for older people arriving at A&E with unexplained symptoms
- A legislated, publicly reported 28-day standard from urgent referral to diagnosis
- A live national dashboard of stage at diagnosis as the scorecard for early detection
- A single 'cancer check at 60' appointment bundling all screening tests
Background: Alpha-fetoprotein (AFP), Barrett's oesophagus, CA 19-9, Early detection, Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Survival gaps between countries and between Black and white women in the same country.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Expert centres
topExpert centres
- via Trastuzumab deruxtecan
- via HER2-positive breast cancer, Triple-negative breast cancer (TNBC)
- via Trastuzumab deruxtecan
- via Triple-negative breast cancer (TNBC)
- via Triple-negative breast cancer (TNBC)
- via Triple-negative breast cancer (TNBC)
- via HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- via Triple-negative breast cancer (TNBC)
- SOLTI Cancer Research GroupBarcelona, ESvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), Trastuzumab +1
- Breast Cancer TrialsNewcastle, NSW, AUvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), Trastuzumab
- Breast International Group (BIG)Brussels, BEvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), Trastuzumab
- GEICAM Spanish Breast Cancer GroupMadrid, ESvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), Palbociclib
- Institut Jules BordetBrussels, BEvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), Trastuzumab
- Instituto Alexander FlemingBuenos Aires, ARvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Trastuzumab, Palbociclib
- via Mammography & tomosynthesis, HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC)
- via HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Palbociclib
- Breast Cancer Research FoundationNew York, USvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC)
- via HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Trastuzumab
- via HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Trastuzumab
- Istituto Oncologico Veneto IRCCSPadua, ITvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Trastuzumab
- NSABP FoundationPittsburgh, PA, USvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Trastuzumab
- Centre Léon BérardLyon, FRvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
- via HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
- via HR-positive / HER2-negative breast cancer, Palbociclib
- ETOP IBCSG Partners FoundationBern, CHvia HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
- via HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- Hospital de Amor (Barretos Cancer Hospital)Barretos, BRvia Mammography & tomosynthesis, HR-positive / HER2-negative breast cancer
- Institut Paoli-CalmettesMarseille, FRvia HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- IRCCS Ospedale San RaffaeleMilan, ITvia HER2-positive breast cancer, Trastuzumab
- Istituto di Candiolo IRCCS (FPO)Candiolo, ITvia HER2-positive breast cancer, Trastuzumab
- Kaiser Permanente Division of ResearchOakland, CA, USvia Mammography & tomosynthesis, HR-positive / HER2-negative breast cancer
- Korle Bu Teaching HospitalAccra, GHvia HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- Lagos University Teaching HospitalLagos, NGvia HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- via HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- via HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- via Trastuzumab, Palbociclib
- via HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- University of Malaya Medical CentreKuala Lumpur, MYvia HR-positive / HER2-negative breast cancer, Triple-negative breast cancer (TNBC)
- via HR-positive / HER2-negative breast cancer, Tamoxifen
- A.C. Camargo Cancer CenterSão Paulo, BRvia HR-positive / HER2-negative breast cancer
- Aarhus University HospitalAarhus, DKvia HR-positive / HER2-negative breast cancer
- Aichi Cancer CenterNagoya, JPvia HR-positive / HER2-negative breast cancer
- Alliance for Clinical Trials in OncologyChicago, IL, USvia Triple-negative breast cancer (TNBC)
- Apollo Hospitals (Apollo Cancer Centres)Chennai, INvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- BC CancerVancouver, BC, CAvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Butaro Cancer Center of ExcellenceButaro, RWvia HR-positive / HER2-negative breast cancer
- Canadian Cancer Trials Group (CCTG)Kingston, ON, CAvia HR-positive / HER2-negative breast cancer
- Cancer Care Alberta (Alberta Health Services)Calgary, AB, CAvia HR-positive / HER2-negative breast cancer
- Cancer Institute (WIA), AdyarChennai, INvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Central Drugs Standard Control OrganizationNew Delhi, INvia Trastuzumab
- Centre Antoine LacassagneNice, FRvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Cleveland Clinic Abu DhabiAbu Dhabi, AEvia HR-positive / HER2-negative breast cancer
- Dan L Duncan Comprehensive Cancer Center, Baylor College of MedicineHouston, TX, USNCI comprehensivevia HR-positive / HER2-negative breast cancer
- Dharmais National Cancer CenterJakarta, IDvia HR-positive / HER2-negative breast cancer
- via HER2-positive breast cancer
- ECOG-ACRIN Cancer Research GroupPhiladelphia, PA, USvia Mammography & tomosynthesis
- Edinburgh Cancer Centre / CRUK Scotland CentreEdinburgh, GBvia HR-positive / HER2-negative breast cancer
- Fundación Arturo López PérezSantiago, CLvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Geneva University Hospitals (HUG)Geneva, CHvia HR-positive / HER2-negative breast cancer
- German Breast Group (GBG)Neu-Isenburg, DEvia Triple-negative breast cancer (TNBC)
- Groote Schuur Hospital / University of Cape TownCape Town, ZAvia HR-positive / HER2-negative breast cancer
- Hacettepe University Cancer InstituteAnkara, TRvia HR-positive / HER2-negative breast cancer
- Hadassah Medical CenterJerusalem, ILvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- HealthCare Global EnterprisesBengaluru, INvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Ho Chi Minh City Oncology HospitalHo Chi Minh City, VNvia HR-positive / HER2-negative breast cancer
- Hospital Clínic de Barcelona / IDIBAPSBarcelona, ESvia HR-positive / HER2-negative breast cancer
- Hospital de Clínicas de Porto AlegrePorto Alegre, BRvia HR-positive / HER2-negative breast cancer
- Hospital Universitari i Politècnic La FeValencia, ESvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, IN, USNCI comprehensivevia Triple-negative breast cancer (TNBC)
- Institut BergoniéBordeaux, FRvia HR-positive / HER2-negative breast cancer
- Institut National d'Oncologie, RabatRabat, MAvia HR-positive / HER2-negative breast cancer
- Institut Salah AzaïezTunis, TNvia HR-positive / HER2-negative breast cancer
- Institute of Oncology LjubljanaLjubljana, SIvia HR-positive / HER2-negative breast cancer
- Instituto Nacional de Câncer (INCA)Rio de Janeiro, BRvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Instituto Nacional de Cancerología (Mexico)Mexico City, MXvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Istanbul University Institute of OncologyIstanbul, TRvia HR-positive / HER2-negative breast cancer
- Juravinski Cancer Centre / Escarpment Cancer Research InstituteHamilton, ON, CAvia HR-positive / HER2-negative breast cancer
- Kenyatta National HospitalNairobi, KEvia HR-positive / HER2-negative breast cancer
- Kidwai Memorial Institute of OncologyBengaluru, INvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- King Hussein Cancer CenterAmman, JOvia HR-positive / HER2-negative breast cancer
- Koo Foundation Sun Yat-Sen Cancer CenterTaipei, TWvia HR-positive / HER2-negative breast cancer
- Korean Cancer Study GroupSeoul, KRvia HER2-positive breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- Max Healthcare (Max Institute of Cancer Care)New Delhi, INvia HR-positive / HER2-negative breast cancer
- via HER2-positive breast cancer
- via HR-positive / HER2-negative breast cancer
- Narayana Health (Mazumdar Shaw Medical Centre)Bengaluru, INvia HR-positive / HER2-negative breast cancer
- National Cancer Center Hospital EastKashiwa, Chiba, JPvia Trastuzumab deruxtecan
- National Cancer Center KoreaGoyang, KRvia Mammography & tomosynthesis
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- National Institute of Oncology, HungaryBudapest, HUvia HR-positive / HER2-negative breast cancer
- National Taiwan University HospitalTaipei, TWvia HER2-positive breast cancer
- via HR-positive / HER2-negative breast cancer
- NRG OncologyPhiladelphia, PA, USvia Triple-negative breast cancer (TNBC)
- Ocean Road Cancer InstituteDar es Salaam, TZvia HR-positive / HER2-negative breast cancer
- via Trastuzumab deruxtecan
- Philippine General HospitalManila, PHvia HR-positive / HER2-negative breast cancer
- QIMR Berghofer Medical Research InstituteBrisbane, AUvia HR-positive / HER2-negative breast cancer
- Rajiv Gandhi Cancer Institute and Research CentreNew Delhi, INvia HR-positive / HER2-negative breast cancer
- Ramathibodi Hospital, Mahidol UniversityBangkok, THvia HR-positive / HER2-negative breast cancer
- Rambam Health Care CampusHaifa, ILvia HR-positive / HER2-negative breast cancer
- Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicago, IL, USNCI comprehensivevia HR-positive / HER2-negative breast cancer
- Rosalind and Morris Goodman Cancer Institute, McGill UniversityMontréal, QC, CAvia HER2-positive breast cancer
- Royal Adelaide HospitalAdelaide, AUvia HR-positive / HER2-negative breast cancer
- via Triple-negative breast cancer (TNBC)
- Shaare Zedek Medical CenterJerusalem, ILvia HR-positive / HER2-negative breast cancer
- Sheba Medical CenterRamat Gan, ILvia HR-positive / HER2-negative breast cancer
- Siriraj Hospital, Mahidol UniversityBangkok, THvia HR-positive / HER2-negative breast cancer
- Society of Surgical OncologyRosemont, IL, USvia HR-positive / HER2-negative breast cancer
- Sunnybrook Odette Cancer CentreToronto, ON, CAvia HR-positive / HER2-negative breast cancer
- SWOG Cancer Research NetworkPortland, OR, USvia Triple-negative breast cancer (TNBC)
- Tata Medical Center, KolkataKolkata, INvia HR-positive / HER2-negative breast cancer
- Tawam HospitalAl Ain, AEvia HR-positive / HER2-negative breast cancer
- Tel Aviv Sourasky Medical CenterTel Aviv, ILvia HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
- via Triple-negative breast cancer (TNBC)
- Tohoku University HospitalSendai, JPvia HR-positive / HER2-negative breast cancer
- Uganda Cancer InstituteKampala, UGvia HR-positive / HER2-negative breast cancer
- UNICANCERParis, FRvia Triple-negative breast cancer (TNBC)
- via HER2-positive breast cancer
- via HR-positive / HER2-negative breast cancer
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer CenterBaltimore, MD, USNCI comprehensivevia HR-positive / HER2-negative breast cancer
- via Triple-negative breast cancer (TNBC)
- Walter and Eliza Hall Institute of Medical ResearchMelbourne, AUvia HR-positive / HER2-negative breast cancer
- Weizmann Institute of ScienceRehovot, ILvia HER2-positive breast cancer
- West Japan Oncology GroupOsaka, JPvia HER2-positive breast cancer
- via HR-positive / HER2-negative breast cancer
- via HR-positive / HER2-negative breast cancer
Questions to ask
topQuestions to ask your oncologist about Breast cancer
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Oestrogen and progesterone receptors, HER2, Ki-67 and grade, Genomic recurrence scores, BRCA1/2 and other germline variants), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Screening
- For my situation (screening), which of the standard options do you recommend and why?Why: Guideline options include: Mammography every one to three years from around age 40 to 50 depending on country; MRI for high-risk women.
Early disease, all types
- For my situation (early disease, all types), which of the standard options do you recommend and why?Why: Guideline options include: Breast-conserving surgery with radiotherapy or mastectomy, sentinel node biopsy, then treatment by receptor type on the subtype pages.
Ductal carcinoma in situ
- For my situation (ductal carcinoma in situ), which of the standard options do you recommend and why?Why: Guideline options include: Surgery with or without radiotherapy and endocrine therapy; active surveillance under study.
Any stage
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “Metastatic disease remains incurable for almost everyone”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Triple-negative and inflammatory breast cancer still have the worst outlook”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
8targets
3drugs
4companies
4Latest papers
topQuery for this cancer: (TITLE:"Breast cancer" OR ABSTRACT:"Breast cancer" OR TITLE:"all types" OR ABSTRACT:"all types" OR TITLE:"Breast carcinoma" OR ABSTRACT:"Breast carcinoma" OR TITLE:"Carcinoma of the breast" OR ABSTRACT:"Carcinoma of the breast") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Breast cancer (all types), not a curated reading list.
Similar pages
not linked directly; found by shared links- JournalBreast cancer
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- JournalThe breast journal
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- JournalJournal of breast imaging
Shares Ductal carcinoma in situ (DCIS), Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- JournalThe Breast
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- JournalClinical breast cancer
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- TrialIMPORT LOW
Shares Hypofractionated radiotherapy, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- JournalJournal of mammary gland biology and neoplasia
Shares Ductal carcinoma in situ (DCIS), HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TrialFAST-Forward
Shares Hypofractionated radiotherapy, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.